Oligodendroglial tumors with marked desmoplasia: Clinicopathologic and molecular features of 7 cases

Mark Jentoft, Caterina Giannini, Sabrina Rossi, Renan Mota, Robert Brian Jenkins, Fausto J. Rodriguez

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Oligodendroglial tumors may rarely display striking desmoplasia resulting in unusual histologic patterns that have not been completely characterized. We reviewed the clinicopathologic findings of 7 such cases. Patients included 4 men and 3 women. Mean age at the time of primary surgery was 49 years (range, 31 to 57 y). All tumors were of World Health Organization grade III (4 anaplastic oligodendrogliomas and 3 anaplastic oligoastrocytomas). Characteristic morphologic features included tumor nests/nodules with surrounding fibrosis/desmoplasia (n=5), cords/single-cell infiltration (n=2), minigemistocytes (n=5), endothelial hypertrophy (n=6), and necrosis (n=1). Mean mitotic index was 9 mitoses per 10 high-power fields. Immunohistochemical studies demonstrated immunoreactivity for PDGFRα 1 to 3+ (5 of 6), PDGFRβ 3+ (n=3 of 3), and EGFR 1 to 2+ (n=5 of 6). p53 protein expression was 1-2+ and MIB-1 labeling index was moderate. Four tumors showed 1p19q codeletion, 1 tumor showed 1p deletion only, and 2 tumors showed intact 1p19q loci. t(1:19) was identified in 2 (of 3) tested cases, both also with 1p19q codeletion, and was absent in the case with 1p loss only. IDH1R132H mutant protein was detected in 3 (of 6) cases, and an IDH mutation (R132S) was identified in an additional case by pyrosequencing. Clinical follow-up was available in 6 (of 7) patients (mean follow-up of 64.2 mo). Five (of 6) developed recurrence/progression at a mean interval of 49.2 months after primary diagnosis. Only 1 patient died of disease, 22.5 months after primary diagnosis. Oligodendroglial tumors with prominent desmoplasia are rare. Most cases demonstrate 1p19q codeletion and IDH1 mutations, and behave as expected for anaplastic oligodendroglial tumors.

Original languageEnglish (US)
Pages (from-to)845-852
Number of pages8
JournalAmerican Journal of Surgical Pathology
Volume35
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Neoplasms
Oligodendroglioma
Mutation
Mitotic Index
Mutant Proteins
Mitosis
Hypertrophy
Fibrosis
Necrosis
Recurrence
Proteins

Keywords

  • 1p19q
  • brain
  • desmoplasia
  • glioma
  • oligoastrocytoma
  • oligodendroglial tumors
  • oligodendroglioma

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Oligodendroglial tumors with marked desmoplasia : Clinicopathologic and molecular features of 7 cases. / Jentoft, Mark; Giannini, Caterina; Rossi, Sabrina; Mota, Renan; Jenkins, Robert Brian; Rodriguez, Fausto J.

In: American Journal of Surgical Pathology, Vol. 35, No. 6, 06.2011, p. 845-852.

Research output: Contribution to journalArticle

@article{c6842830a7934549b0f4cd4266bc623e,
title = "Oligodendroglial tumors with marked desmoplasia: Clinicopathologic and molecular features of 7 cases",
abstract = "Oligodendroglial tumors may rarely display striking desmoplasia resulting in unusual histologic patterns that have not been completely characterized. We reviewed the clinicopathologic findings of 7 such cases. Patients included 4 men and 3 women. Mean age at the time of primary surgery was 49 years (range, 31 to 57 y). All tumors were of World Health Organization grade III (4 anaplastic oligodendrogliomas and 3 anaplastic oligoastrocytomas). Characteristic morphologic features included tumor nests/nodules with surrounding fibrosis/desmoplasia (n=5), cords/single-cell infiltration (n=2), minigemistocytes (n=5), endothelial hypertrophy (n=6), and necrosis (n=1). Mean mitotic index was 9 mitoses per 10 high-power fields. Immunohistochemical studies demonstrated immunoreactivity for PDGFRα 1 to 3+ (5 of 6), PDGFRβ 3+ (n=3 of 3), and EGFR 1 to 2+ (n=5 of 6). p53 protein expression was 1-2+ and MIB-1 labeling index was moderate. Four tumors showed 1p19q codeletion, 1 tumor showed 1p deletion only, and 2 tumors showed intact 1p19q loci. t(1:19) was identified in 2 (of 3) tested cases, both also with 1p19q codeletion, and was absent in the case with 1p loss only. IDH1R132H mutant protein was detected in 3 (of 6) cases, and an IDH mutation (R132S) was identified in an additional case by pyrosequencing. Clinical follow-up was available in 6 (of 7) patients (mean follow-up of 64.2 mo). Five (of 6) developed recurrence/progression at a mean interval of 49.2 months after primary diagnosis. Only 1 patient died of disease, 22.5 months after primary diagnosis. Oligodendroglial tumors with prominent desmoplasia are rare. Most cases demonstrate 1p19q codeletion and IDH1 mutations, and behave as expected for anaplastic oligodendroglial tumors.",
keywords = "1p19q, brain, desmoplasia, glioma, oligoastrocytoma, oligodendroglial tumors, oligodendroglioma",
author = "Mark Jentoft and Caterina Giannini and Sabrina Rossi and Renan Mota and Jenkins, {Robert Brian} and Rodriguez, {Fausto J.}",
year = "2011",
month = "6",
doi = "10.1097/PAS.0b013e3182189693",
language = "English (US)",
volume = "35",
pages = "845--852",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Oligodendroglial tumors with marked desmoplasia

T2 - Clinicopathologic and molecular features of 7 cases

AU - Jentoft, Mark

AU - Giannini, Caterina

AU - Rossi, Sabrina

AU - Mota, Renan

AU - Jenkins, Robert Brian

AU - Rodriguez, Fausto J.

PY - 2011/6

Y1 - 2011/6

N2 - Oligodendroglial tumors may rarely display striking desmoplasia resulting in unusual histologic patterns that have not been completely characterized. We reviewed the clinicopathologic findings of 7 such cases. Patients included 4 men and 3 women. Mean age at the time of primary surgery was 49 years (range, 31 to 57 y). All tumors were of World Health Organization grade III (4 anaplastic oligodendrogliomas and 3 anaplastic oligoastrocytomas). Characteristic morphologic features included tumor nests/nodules with surrounding fibrosis/desmoplasia (n=5), cords/single-cell infiltration (n=2), minigemistocytes (n=5), endothelial hypertrophy (n=6), and necrosis (n=1). Mean mitotic index was 9 mitoses per 10 high-power fields. Immunohistochemical studies demonstrated immunoreactivity for PDGFRα 1 to 3+ (5 of 6), PDGFRβ 3+ (n=3 of 3), and EGFR 1 to 2+ (n=5 of 6). p53 protein expression was 1-2+ and MIB-1 labeling index was moderate. Four tumors showed 1p19q codeletion, 1 tumor showed 1p deletion only, and 2 tumors showed intact 1p19q loci. t(1:19) was identified in 2 (of 3) tested cases, both also with 1p19q codeletion, and was absent in the case with 1p loss only. IDH1R132H mutant protein was detected in 3 (of 6) cases, and an IDH mutation (R132S) was identified in an additional case by pyrosequencing. Clinical follow-up was available in 6 (of 7) patients (mean follow-up of 64.2 mo). Five (of 6) developed recurrence/progression at a mean interval of 49.2 months after primary diagnosis. Only 1 patient died of disease, 22.5 months after primary diagnosis. Oligodendroglial tumors with prominent desmoplasia are rare. Most cases demonstrate 1p19q codeletion and IDH1 mutations, and behave as expected for anaplastic oligodendroglial tumors.

AB - Oligodendroglial tumors may rarely display striking desmoplasia resulting in unusual histologic patterns that have not been completely characterized. We reviewed the clinicopathologic findings of 7 such cases. Patients included 4 men and 3 women. Mean age at the time of primary surgery was 49 years (range, 31 to 57 y). All tumors were of World Health Organization grade III (4 anaplastic oligodendrogliomas and 3 anaplastic oligoastrocytomas). Characteristic morphologic features included tumor nests/nodules with surrounding fibrosis/desmoplasia (n=5), cords/single-cell infiltration (n=2), minigemistocytes (n=5), endothelial hypertrophy (n=6), and necrosis (n=1). Mean mitotic index was 9 mitoses per 10 high-power fields. Immunohistochemical studies demonstrated immunoreactivity for PDGFRα 1 to 3+ (5 of 6), PDGFRβ 3+ (n=3 of 3), and EGFR 1 to 2+ (n=5 of 6). p53 protein expression was 1-2+ and MIB-1 labeling index was moderate. Four tumors showed 1p19q codeletion, 1 tumor showed 1p deletion only, and 2 tumors showed intact 1p19q loci. t(1:19) was identified in 2 (of 3) tested cases, both also with 1p19q codeletion, and was absent in the case with 1p loss only. IDH1R132H mutant protein was detected in 3 (of 6) cases, and an IDH mutation (R132S) was identified in an additional case by pyrosequencing. Clinical follow-up was available in 6 (of 7) patients (mean follow-up of 64.2 mo). Five (of 6) developed recurrence/progression at a mean interval of 49.2 months after primary diagnosis. Only 1 patient died of disease, 22.5 months after primary diagnosis. Oligodendroglial tumors with prominent desmoplasia are rare. Most cases demonstrate 1p19q codeletion and IDH1 mutations, and behave as expected for anaplastic oligodendroglial tumors.

KW - 1p19q

KW - brain

KW - desmoplasia

KW - glioma

KW - oligoastrocytoma

KW - oligodendroglial tumors

KW - oligodendroglioma

UR - http://www.scopus.com/inward/record.url?scp=79958005779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958005779&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e3182189693

DO - 10.1097/PAS.0b013e3182189693

M3 - Article

C2 - 21552114

AN - SCOPUS:79958005779

VL - 35

SP - 845

EP - 852

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 6

ER -